At meeting held on 09 December 2017
The Board of Thyrocare Technologies has decided to defer a decision on payment of interim dividend pending assessment of requirement of funds to meet the capex requirements of the wholly-owned subsidiary, Nueclear Healthcare Limited, since the Company has already decided to give them loan to help them acquire costly equipment like Cyclotron, PET-CT Scan machines, etc., to set up additional scanning centres; to invest upto Rs. 20 crores in Equinox Labs Private Limited, Navi Mumbai-Rs. 10 crores in cash and by divestment of Water Testing Business to them for Rs. 10 crores, on slump sale basis, and to administer the ESOP schemes hereafter directly instead of through the Trust.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app